November 01, 2026

To,
The BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001
Scrip Code: 540737

Dear Sir/Ma'am,

Sub: Investor Presentation

With reference to the captioned subject, we enclose herewith the Investor Presentation with respect to Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026.

Kindly take the same on your record.

Thanking You,

Yours faithfully

For Shree Ganesh Remedies Limited

AKANKSHA
Digitally signed by AKANKSHA
Date: 2026.11.01 19:01:27 +05'30'

Akanksha
Company Secretary and Compliance Officer

Enc. a/a

Investor Presentation

Q2 & H1FY27

Innovate.
React.
Transform.















SHREE GANESH **REMEDIES** LIMITED

excelling in chemistry

Inside the Presentation



Quarterly Highlights

04 Management Commentary
05 P&L Summary
06 Balance Sheet Summary
07 Cash Flow Summary



About the Business

09 Excellence in Complex Chemistry
10 Unparalleled Expertise in Advanced Chemical Synthesis
12 Unmatched Technology Prowess In Complex Chemical Reactions
13 Tailored Solutions Through Mastered Chemistry and Technology
14 Strategic Product Selection Criteria
15 Our Evolving Business Model
16 Collaborating With Industry Leaders
17 Ankleshwar Site Expansion Fuelling Our Growth Strategy
18 Infrastructure at Ankleshwar Site
19 Dahej Land Acquisition Setting the Stage for Large Scale Projects
20 Driving Innovation Through Strategic R&D Investments
21 State-of-the-Art R&D Infrastructure
22 State-of-the-Art Pilot Infrastructure
23 Accreditations that Speak to Our Comprehensive Standards
24 Driving Innovation and Growth
25 Ensuring Health and Safety
26 Protecting the Environment With Sustainable Practices



Financial Highlights

28 5 Year Summary
29 Key Ratios
30 P&L Summary
31 Balance Sheet Summary
32 Cash Flow Summary



Investment Merits

34 Investment Case

Forward Looking Statement

In so far as forecasts or expectations are expressed in this presentation or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Shree Ganesh Remedies Limited does not assume an obligation to update the forecasts, expectations or statements contained in this presentation.

Quarterly Highlights

Management Commentary 04

P&L Summary 05

Balance Sheet Summary 06

Cash Flow Summary 07



Management Commentary

FY27 began on a challenging note for the Company. Subdued demand from Europe and a difficult operating environment weighed on our first-quarter performance. Over the past three months, we have worked steadily through these challenges, and this is reflected in an improved performance in Q2FY27.

Much of this improvement has come from our core pharmaceutical intermediates business, where we sharpened our focus on the domestic market to make up for softer exports. Alongside this, we have begun to see improved traction from our European customers, which gives us confidence that the core business will recover to its earlier levels over the next few quarters. We have also broadened our portfolio during the quarter by commencing commercial production of two new pharmaceutical intermediates, one for anti-diabetic and one for cardiovascular applications. Both have received an encouraging response in the domestic market, and we plan to take them to export markets in the coming quarters.

While volumes are on the path to recovery, they remain below earlier levels, and this has put some pressure on our margins. Raw material prices added to this pressure, rising significantly and staying volatile through the quarter. We expect input costs to ease as geopolitical conditions stabilise, and margins to normalise as our sales return to earlier levels. Throughout, we remain focused on healthy profitability, including on the new products we are developing.

As we work towards this recovery, we continue to build the businesses that will drive our next phase of growth. Our CRAMS business has made strong progress during the quarter. On our specialty chemicals project for South-East Asian markets, we have successfully completed the pilot trials, and the batches are now undergoing stability testing, with commercial supplies expected from Q1FY28. A second specialty chemicals product for the same region has cleared laboratory trials and moved to the pilot stage. In Europe, we are making positive progress on two molecules for pharmaceutical and agrochemical applications. To support this pipeline, construction of Block 7A is now complete and trials have begun.

This year has brought its own set of challenges, and we have responded by strengthening our domestic presence, adding to our product portfolio and advancing our CRAMS pipeline. With the core business recovering, new products gaining traction and new capacity coming online, we look forward to a stronger performance in the periods ahead.



Gunjan Kothia
Promoter, Head of Business Development & Innovation

QUARTERLY HIGHLIGHTS

P&L Summary

YoY Change

-23%	-59%	-67%
Revenue	EBITDA	PAT

PARTICULARS (₹ IN CRORES)	Q2FY26	Q1FY27	Q2FY27	YoY Change	QoQ Change	H1FY26	H1FY27	YoY Change
Revenue from Operations	**30.32**	**14.36**	**23.29**	**-23%**	**62%**	**54.98**	**37.65**	**-32%**
Total Income	31.00	15.30	24.70	-20%	61%	56.33	40.00	-29%
Operating Expenses	20.70	11.01	19.36	-6%	76%	38.07	30.37	-20%
EBITDA (Excluding OI & EI)	**9.62**	**3.35**	**3.94**	**-59%**	**17%**	**16.92**	**7.29**	**-57%**
EBITDA %	**31.7%**	**23.3%**	**16.9%**	**-1,483 bps**	**-644 bps**	**30.8%**	**19.4%**	**-1141bps**
Finance Cost	1.01	0.32	0.58	-43%	80%	1.95	0.89	-54%
Depreciation & Ammortization	2.59	2.44	2.50	-3%	3%	5.01	4.94	-1%
PBT	6.71	1.53	2.26	-66%	48%	11.31	3.79	-66%
PAT	**4.96**	**1.12**	**1.63**	**-67%**	**46%**	**8.41**	**2.75**	**-67%**
EPS (₹)	3.86	0.87	1.28	-67%	47%	6.55	2.15	-67%

Balance Sheet Summary

PARTICULARS (₹ IN CRORES)	FY26	H1FY27
Shareholders' Funds	**163.02**	**165.79**
Non-Current Liabilities	**23.03**	**22.61**
Long Term Borrowings	21.25	20.62
Current Liabilities	**21.69**	**21.97**
Short Term Borrowings	9.42	5.37
Trade Payables	9.44	14.84
Total Equity and Liabilities	**207.74**	**210.37**
Non-Current Assets	**121.91**	**122.85**
Tangible Assets	68.08	64.63
CWIP	12.38	16.30
Current Assets	**85.83**	**87.52**
Inventories	24.01	33.53
Trade Receivables	32.57	21.12
Cash & Bank Balances	13.45	17.36
Investments	12.45	11.38
Total Assets	**207.74**	**210.37**

Cash Flow Summary

PARTICULARS (₹ IN CRORES)	**H1FY26**	**H1FY27**
Cash from Operating Activities	**17.66**	**14.64**
Cash from Investing Activities	-8.23	-5.17
Cash from Financing Activities	-5.73	-5.55
Net Cash Flow	**3.70**	**3.92**
Cash at the Beginning of Year	11.12	13.36
Cash at the End of Year	**14.82**	**17.28**

About the Business

Excellence in Complex Chemistry	09
Unparalleled Expertise in Advanced Chemical Synthesis	10
Unmatched Technology Prowess In Complex Chemical Reactions	12
Tailored Solutions Through Mastered Chemistry and Technology	13
Strategic Product Selection Criteria	14
Our Evolving Business Model	15
Collaborating With Industry Leaders	16
Ankleshwar Site Expansion Fuelling Our Growth Strategy	17
Infrastructure at Ankleshwar Site	18
Dahej Land Acquisition Setting the Stage for Large Scale Projects	19
Driving Innovation Through Strategic R&D Investments	20
State-of-the-Art R&D Infrastructure	21
State-of-the-Art Pilot Infrastructure	22
Accreditations that Speak to Our Comprehensive Standards	23
Driving Innovation and Growth	24
Ensuring Health and Safety	25
Protecting the Environment With Sustainable Practices	26



Excellence in Complex Chemistry



Established Expertise

Over 21 years of excellence in chemical manufacturing, specialising in pharmaceutical intermediates and speciality chemicals.



Strategic Expansions

Continuous investments in new manufacturing blocks and R&D centers to enhance production capacity and innovation.



Global Reach

Serving over 21 countries, including key markets in the EU and the US, with a robust export portfolio.



Trusted Partner

Trusted partner for leading global companies, offering reliable and high-quality custom manufacturing solutions.



Innovative Capabilities

Equipped with state-of-the-art R&D facility, enabling complex chemical synthesis and innovation.



Sustainable Practices

Committed to environmental sustainability with ISO 14001, certification and initiatives in solar energy and waste recycling.

Unparalleled Expertise in Advanced Chemical Synthesis



Core Strengths in Mastered Chemistries

Our company excels in the following core chemistries, with dedicated manufacturing blocks for each:

1. Halogenation

- **Chlorination:** Using Thionyl Chloride, Sulphuryl Chloride, Oxalyl Chloride, Mesyl Chloride, HCL gas, and Chlorine gas, and under UV light.
- **Bromination:** Employing Bromine, HBr, other bromide salts, and under UV light.
- **Iodination:** Using Iodine, KI, and Copper Iodide.

2. Reduction

- **Catalytic H2 Reduction:** Up to 40 bar using Ra-Ni, Pt/C, Pd/C, and Rt/C.
- **Hydride Salts:** Effective reduction processes using salts of Na, Al and K.
- **Pyrophoric Reagents:** Using reagents such as Vitride and DIBAL.

3. Methylation, Alkylation & C-C Bond Formation

- **Friedel-Crafts Reaction:** Using AlCl3 and FeCl3 and other catalysts.
- **DMS & DES Alkylation:** From room temperature to high temperature.
- **Pd-Catalyzed Coupling:** Including Heck and Suzuki reactions.
- **Grignard Reactions:** Using Mg or AlkMgX/ether; Vinyl MgCl.

Unparalleled Expertise in Advanced Chemical Synthesis (Continued)

Additional Chemistries

While we currently do not have dedicated blocks for the following chemistries, we have established a strong foothold and are evaluating the possibility of adding dedicated blocks in the future

Oxidation:
Using TEMPO, NaOCl, Permanganate Salts, and metals such as Fe, Cu, Co, and Cr.


Low-Temperature Chemistry:
Metalorganic reactions, selective oxidations and hydrogenations, cryogenic quenching, and selective C-C bond formation.

Other Reaction Capabilities

Heterocycle Synthesis	1
Nitration	2
Chiral Resolution	3
Esterification	4
Dehalogenation	5
Diels-Alder Reaction	6
Hydrolysis	7
Silyl Derivatives	8
Oxime Formation	9

Unmatched Technology Prowess In Complex Chemical Reactions

We pride ourselves on our advanced technological capabilities, which enable us to handle some of the most complex chemical reactions with precision and efficiency. These capabilities form a core strength of our operations and set us apart in the industry.



Key Technological Capabilities

Liquid-Gas Reaction: Expertise in managing reactions involving both liquid and gas phases, ensuring optimal reaction conditions and high yields.	1
High-Pressure Reaction: Proficiency in conducting reactions under high pressure, allowing for enhanced reaction rates and the synthesis of unique compounds.	2
Cryogenic Reaction: Skilled in performing reactions at extremely low temperatures, crucial for maintaining the stability of sensitive intermediates and achieving selective transformations.	3
Photo-Catalytic Reaction: Utilisation of light to drive chemical reactions, offering an environmentally friendly approach and enabling the synthesis of complex molecules.	4
Thin-Film Distillation: Advanced techniques in thin-film distillation for the separation of high-boiling and heat-sensitive substances, ensuring product purity and quality.	5
High Fraction Distillation: Mastery in high fraction distillation processes, allowing for the precise separation of complex mixtures into their individual components.	6

Tailored Solutions Through Mastered Chemistry and Technology



Over the years, we have honed our chemistry skills and mastered complex reactions and their requisite technological capabilities. Leveraging this expertise, we have delivered bespoke solutions to our clients across the globe, catering to a wide range of industries. By mastering these chemistry skills and complex technological processes, we have positioned ourselves as a skill-based company capable of creating a diverse array of products tailored to our customers' specific needs.

Products by chemistry

- Chloro-Alkyl Amines HCl Salts
- Cyclopropane Derivatives
- Cyclobutane Derivatives
- Carboxylic Acids & Acid Chlorides
- Aliphatic Chlorides & Bromides
- Aliphatic Alcohols & Acetates
- Furfural Derivatives
- Aromatic Esters & Acetates

Industries Catered

- Human and Veterinary Health
- Agrochemical Industry
- Polymer Industry
- Electronics Industry

Strategic Product Selection Criteria

Our product selection philosophy ensures that we only engage in manufacturing products that align with our core strengths and strategic goals. Each product must meet the following criterias

Chemistry Skillset
The product must fall within the chemistry skills we have mastered.

1

Technology Skillset
We must be capable of handling the complex processes involved, or we should receive a technology transfer from the client to learn and add another offering.

2

Backward Integration
We must be backward integrated in the manufacturing process to maintain cost control.

3

Multi-Chemistry Involvement
The product should involve multiple chemistries in its manufacturing process. This complexity reduces competition by focusing on products requiring 3-4 different chemistries rather than just 3-4 reaction steps.

4

Margin Profile
The product must meet our internal benchmarks for sustainable margins over the long term. We only pursue products that can maintain these margins.

5

Our Evolving Business Model

Pharmaceutical Intermediates

Inception
Since Company's inception in 2004

Focus
Intermediates for Off-patent and generic drugs requiring control over complex chemistry

Revenue Contribution
Previously >90%, now <60%

Regulatory Requirements
Intermediates not requiring stringent regulatory approvals

Customer Base
Established names, catering to marquee global customers

Project Sizes
Multiple Products in small batch sizes manufactured on campaign basis in multi purpose plants

Strategic Position
Manufacturing multiple products with prioritizing profitability

Speciality and Fine Chemicals

Inception
Entered in 2010

Focus
Moving towards patented molecules and customer specific innovative molecules requiring strong technical know how

Revenue Contribution
Expected to reach > 60% in coming years

Regulatory Requirements
Leveraging our extensive experience working with top European pharmaceutical companies, we have developed robust infrastructure and documentation processes, providing us with strong systematic and regulatory expertise to rapidly scale up this vertical.

Customer Base
At inflexion point, scaling up with global giants

Project Sizes
Evolved from 20-50 tonnes/year to 80-100 tonnes/year, now receiving inquiries for > 500 tonnes per year

Strategic Position
We have advanced from being the third to the second supplier for medium-sized projects for the client, further strengthening our position as the preferred custom synthesis partner of choice from India.

Collaborating With Industry Leaders

Dipharma Since 1949

BASF We create chemistry

Lonza

dottikon

Cambrex

AARTI INDUSTRIES LIMITED

Dr. Reddy's

LAURUS Labs Knowledge . Innovation . Excellence

Cipla

Ankleshwar Site Expansion Fuelling Our Growth Strategy

Unit 1

Production Blocks

- Currently 7 functional blocks
- Block 8 added in FY24
- Block 7: To be commissioned in H1FY27
- On going CAPEX for Plant 7
- Commissioning of all new Pilot Plant: implementing Automation and Flow Chemistries in Q4FY26

Strategic Focus

Continuing manufacture of:

- Pharmaceutical intermediates
- Complex and niche Specialty Chemicals
- Fine Chemicals
- Moving up the value chain in Fine Chemicals
- Targeting products fitting our selection criteria



Block 8

Capability & R&D Expansion - Unit 1

- Completed CAPEX of Plant 8 in FY25
- Projected CAPEX for Plant 7 is estimated at ~₹20 Crores

FY26 - ₹15 crores

CAPEX outlay for new expansion of new manufacturing block and bolstering R&D intitatives

Infrastructure at Ankleshwar Site

35
Glass Lined Reactors
1000 to 25,000 Ltr
*2 cryogenic (-30 Deg C)

28
Stainless Steel Reactors
1000 to 15,000 Ltr
*1 cryogenic (-40 Deg C)

3
Autoclave Reactors
2000 Ltr
*3 autoclaves
(up to 40 bar)

9
Dryers
1000 to 2,500 Ltr
*Atmospheric &
vacuum dryer

8
Distillation Setup
Upto 70 Stages
*High vacuum upto 1 mbar
*Short path distillation
*Thin-flim distillation

4
Warehouse
Upto 500 Pallets

Dahej Land Acquisition Setting the Stage for Large Scale Projects

Site Development
- Initiated the construction of common infrastructure, utilities, and warehousing facilities

Strategic Use
- Dahej site to host projects with large corporates for custom product requirements at large scale
- Capital-intensive plants with high automation

Project Evaluation
- Multiple projects currently being evaluated and discussed with customers
- Due to signed NDAs, customer and product details cannot be disclosed at this time

Expansion Plan
- Expansion at Dahej site to be carried out in a phased manner

Land Expansion

Acquired 40,554 sq m land parcel at Dahej in 2022 for future expansion

₹ 11 crores

Capital outlay for land acquisition

Driving Innovation Through Strategic R&D Investments



R&D Lab Recognition

Recognised by DSIR (Department of Scientific and Industrial Research), Central Government

R&D and Process Team Composition

40

Total Team Members

Global Expansion

Exploring the setup of R&D facilities in foreign locations to further ramp up research initiatives

R&D Head Profile

- Has 18 years of experience
- Has two patents to his name

State-of-the-Art R&D Infrastructure

Key Facilities

Advanced Analytical Labs
Equipped with cutting-edge instruments for precise analysis

Pilot Plants
For scale-up studies and process optimisation

Dedicated Synthesis Labs
For novel compound development

High-Performance Computing (HPC)
For molecular modelling and simulations

Safety and Compliance Labs
Ensuring adherence to global standards

Collaboration Spaces
For fostering innovation and teamwork



Future Plans

Continued investment in infrastructure to support advanced research

Expansion of facilities to accommodate growing R&D needs

Adding a new R&D block for pilot trials and scale-ups to speed up development.

State-of-the-Art Pilot Infrastructure

As a critical enabler of our growth strategy, our Pilot Plant stands at the forefront of innovation, bridging the gap between research and commercial production.

Vital Role in R&D and Scale-Up

- Accelerates the transition of new molecules from laboratory research to commercial scale.
- Supports technology scale-up for both new and existing molecules, ensuring seamless integration into full-scale manufacturing.

Expansion and Enhanced Infrastructure

- In response to the success of our existing Pilot Plant, we are commissioning a brand-new facility.
- The expanded Pilot Plant will feature advanced technologies and enhanced reaction capabilities, further strengthening SGRL's position as the preferred custom synthesis partner of choice from India.

Commercial Manufacturing Capabilities

- Functions as a flexible commercial site for the production of complex chemistry molecules, catering to niche and high-value projects.
- Enables rapid response to evolving market demands and client requirements.

State-of-the-Art Infrastructure

- Equipped with versatile reactors and process equipment to handle a wide spectrum of chemistries and scales.
- Designed for safety, efficiency, and compliance with international quality standards.



Pilot Facilities

12 Reactors with a Total capacity of 6900 Ltr	**08** Glass Lined Reactors From 600 to 1000 Ltr	**04** Stainless Steel Reactors From 600 to 1000 Ltr
03 Filter Dryers (up to 250 Ltr) ANFD, RCVD & VTD	**02** Hydrogenation Reactors 2 Ltr & 25 Ltr, 100 bar	**04** Reactors with a Total capacity of 6900 Ltr

Accreditations that Speak to Our Comprehensive Standards

Indian GMP Certified Manufacturing Facility

ISO 9001:2015 Certified (Bureau Veritas)

ISO 14001:2015 Certified (Bureau Veritas)

ISO 45001:2018 Certified (CCPL)

DSIR Recognised In-house R&D Lab

Bronze Certified by EcoVadis

ISO 14064:3 Certified (Greenhouse Emission Control)

Halal Certified

Driving Innovation and Growth



Chandu Kothia

Founding Promoter,
Managing Director

Qualifications: Master of Science & Chemistry

Experience: Visionary leader with multiple decades of experience in the chemical industry.

Role: Provides strategic direction and leadership to SGRL.



Gunjan Kothia

Promoter,
Head of Business Development & Innovation

Qualifications: BE in Chemical Engineering (GTU), MSc in Fine Chemicals and Polymers from University of Leeds (UK)

Experience: Commercial portfolio management, growth strategy development, and technology development.

Role: Drives commercial and technological advancements within the company.



Parth Kothia

Promoter,
Whole Time Director, CFO

Qualifications: BTech in Chemical Engineering from Dharmsinh Desai University, Masters in Global Finance from Fordham University (NYC, USA)

Experience: Finance and growth strategy implementation, strategic financial implementations.

Role: Oversees financial strategy and corporate relations.

Ensuring Health and Safety



Technical Measures

Closed charging and discharging systems

Closed sampling for safety

Air locks to avoid cross-contamination



Personal Protection Equipment

Working clothes with glasses and gloves

Full protection suits

Dust protection masks

Protection masks with filters as per gases

Forced air ventilation



Organisational Measures

HAZOP compatible study on raw materials and finished products

Regular training on safety measures

Monitoring hazardous parameters




Health Check

Regular health check-ups

Health insurance coverage for employees

Protecting the Environment With Sustainable Practices



- Conversion of flue gases to by-products for environmental protection
- In-house wastewater treatment for recycling of water
- High-temperature incinerator for toxic waste
- Biological waste water treatment plant
- Implemented a 2.5 MW solar power park, expected to generate up to 70% of our electricity from renewable sources.


Financial Highlights

5 Year Summary	28
Key Ratios	29
P&L Summary	30
Balance Sheet Summary	31
Cash Flow Summary	32




5 Year Summary


Revenue from Operations
(₹ IN CRORES)




Profit After Tax
(₹ IN CRORES)



EBITDA & EBITDA Margins
(₹ IN CRORES & IN %)




EPS
(IN ₹)




Key Ratios


ROE
(IN %)




ROCE
(IN %)



Equity & Debt to Equity Ratio
(₹ IN CRORES & IN TIMES)



Cash from Operating Activities
(₹ IN CRORES)



P&L Summary

CAGR
(FY21-25)

11%	18%	7%
Revenue	EBITDA	PAT

PARTICULARS (₹ IN CRORES)	FY22	FY23	FY24	FY25	FY26
Revenue from Operations	**71.29**	**91.36**	**125.90**	**108.60**	**109.29**
Total Income	74.86	92.07	128.96	112.33	112.32
Operating Expenses	53.37	67.92	84.09	69.38	74.27
EBITDA (Excluding OI & EI)	**17.92**	**23.44**	**41.81**	**39.21**	**35.02**
EBITDA %	**25.1%**	**25.7%**	**33.2%**	**36.1%**	**32.0%**
Finance Cost	0.15	0.18	0.60	2.08	3.56
Depreciation & Ammortization	3.34	3.74	6.11	9.57	10.47
PBT	18.01	20.24	38.17	31.30	24.01
PAT	**13.40**	**15.18**	**28.12**	**23.10**	**17.77**
EPS (₹)	10.96	12.54	22.35	17.98	13.84

Balance Sheet Summary

PARTICULARS (₹ IN CRORES)	FY22	FY23	FY24	FY25	FY26
Shareholders' Funds	**61.57**	**87.20**	**122.11**	**145.19**	**163.02**
Non-Current Liabilities	**0.40**	**30.66**	**30.16**	**30.60**	**23.03**
Long Term Borrowings	0.00	30.44	29.12	29.48	21.25
Current Liabilities	**15.04**	**20.11**	**18.68**	**16.18**	**21.69**
Short Term Borrowings	0.00	2.58	7.19	8.76	9.42
Trade Payables	9.47	15.44	8.19	5.97	9.44
Total Equity and Liabilities	**77.02**	**137.97**	**170.94**	**191.98**	**207.74**
Non-Current Assets	**32.11**	**75.75**	**100.82**	**114.45**	**121.91**
Tangible Assets	26.72	20.92	42.91	57.91	68.08
CWIP	3.09	15.16	16.63	8.34	12.38
Current Assets	**44.91**	**61.20**	**70.13**	**77.53**	**85.83**
Inventories	13.64	18.18	24.99	22.02	24.01
Trade Receivables	18.38	28.11	20.33	22.27	32.57
Cash & Bank Balances	3.88	11.54	16.19	9.99	13.45
Investments	0.00	0.00	4.66	18.26	12.45
Total Assets	**77.02**	**137.97**	**170.94**	**191.98**	**207.74**

Cash Flow Summary

PARTICULARS (₹ IN CRORES)	**FY22**	**FY23**	**FY24**	**FY25**	**FY26**
Cash from Operating Activities	**13.42**	**17.10**	**30.45**	**30.66**	**23.75**
Cash from Investing Activities	(11.91)	(51.09)	(33.09)	(35.66)	(9.89)
Cash from Financing Activities	(1.09)	38.66	9.85	(1.06)	(11.70)
Net Cash Flow	**0.42**	**4.67**	**7.21**	**(6.05)**	**2.17**
Cash at the Beginning of Year	3.47	3.88	8.66	15.86	9.90
Cash at the End of Year	**3.88**	**8.66**	**15.86**	**9.90**	**13.36**

Investment Merits

Investment Case 34



03

Investment Case

Lean Balance Sheet:
The company maintains a strong financial position with minimal debt, ensuring financial stability and flexibility for future growth.

Experienced Management at the Helm:
Led by a seasoned management team with a proven track record, Shree Ganesh Remedies Limited benefits from strategic leadership and industry expertise.


Increasing Focus on Complex Molecules and Niche Specialty Chemicals:
The company is strategically shifting towards complex and niche specialty chemicals, positioning itself in high growth market segments.

Available Land for Further Capacity Expansions:
With ample land availability, Shree Ganesh Remedies Limited is well-equipped to scale operations and meet the growing demand.

Humongous Addressable Opportunity Size:
The company is poised to tap into vast market opportunities, driven by increasing demand for niche customised chemical solutions.

Market Statistics

Shareholding Pattern



Promoter	**72.83%**
Public	**27.17%**

Shareholding Data as on 30th September 2026

CURRENT MARKET PRICE	**₹ 617.25**
52 WEEK HIGH/LOW	**₹ 749.85 / 477.05**
MARKET CAPITALIZATION	**₹ 792.24 Cr**
SHARES OUTSTANDING	**1.28 Cr**
BSE SCRIP CODE	**540737**

Market Price Data as on 30th October 2026

Contact Us

Shree Ganesh Remedies Limited
Headquarters: Plot No. 6002, 6003, 6011 & 6012,
GIDC Estate, Ankleshwar,
Gujarat India – 393002












Akanksha Choudhary
Company Secretary
Shree Ganesh Remedies Limited
investors@ganeshremedies.com

Abhishek Mehra
Investor Relations Advisors
TIL Advisors Private Limited
abhishek@theinvestmentlab.in
+91 95588 14500